China Association of Chinese Medicine Blood Disease Branch. Essential viewpoints of prestigious experts on TCM treatment of hematological diseases Ⅲ[J]. Journal of beijing university of traditional chinese medicine, 2023, 46(12): 1772-1776.
DOI:
China Association of Chinese Medicine Blood Disease Branch. Essential viewpoints of prestigious experts on TCM treatment of hematological diseases Ⅲ[J]. Journal of beijing university of traditional chinese medicine, 2023, 46(12): 1772-1776. DOI: 10.3969/j.issn.1006-2157.2023.12.019.
Essential viewpoints of prestigious experts on TCM treatment of hematological diseases Ⅲ
In order to summarize the academic thoughts and clinical experience of prestigious traditional Chinese medicine (TCM) hematological experts
China Association of Chinese Medicine Blood Disease Branch and the Hematological Diseases' Innovative Research and Transformation Platform of China Association of Chinese Medicine have summarized the academic thoughts and clinical experience of 15 TCM and integrated TCM and western medicine experts such as ZHOU Aixiang. Investigators summarized the clinical diagnosis and treatment experience and academic thoughts of Professors KE Weijun
DAI Ximeng
CHEN Anmin
MA Rou
LI Jianhua
and JIANG Hongyu. Among them
Professor KE Weijun treats hematological diseases with TCM and western medicine and emphasizes the relationship between healthy qi and pathogenic qi based on the evolution rule of disease and syndrome. Professor DAI Ximeng establishes the treatment principle with kidney deficiency as the core in the treatment of aplastic anemia
and takes the lead in the application of
Liushen
Pill in the treatment of leukemia. Professor CHEN Anmin puts forward the theory of "four-dimensional blood production" and "six-in-one co-treatment" in the treatment of hematological diseases. Professor MA Rou adopts a combination of TCM and western medicine to treat hematological diseases based on syndrome differentiation
and is the first to apply
Qinghuang
Powder to treat myelodysplastic syndrome. Professor LI Jianhua puts forward a new hypothesis of "the pathogenesis of enzyme injury first" in aplastic anemia
and constructs a more mature diagnosis and treatment model of integrated TCM and western medicine. Professor JIANG Hongyu proposes a new model of treating aplastic anemia in Chinese medicine
which is a combination of disease
syndrome
and concurrent differentiation and treatment
"triple diagnosis and treatment"
and tertiary prevention of morbidity and recurrence. The purpose of this initiative is to create a co-prosperity body to summarize and build on the experience of experts in TCM for the treatment of hematological disorders
to further enrich and improve the system of inheritance and innovation
and to cultivate and improve the diagnosis and treatment of hematological diseases.